<DOC>
	<DOC>NCT01678807</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety of two doses (6 Development Units [DU] and 12 DU) of MK-8237 sublingual tablets compared to Placebo in adolescents with house dust mite-induced allergic rhinitis/rhinoconjunctivitis. The primary hypothesis is that at least one dose of MK-8237 sublingual tablet is safe and well-tolerated in adolescents with house dust mite-induced allergic rhinitis/rhinoconjunctivitis.</brief_summary>
	<brief_title>Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
	<criteria>History of physiciandiagnosed allergic rhinitis/rhinoconjunctivitis to house dust of at least 6 months duration (with or without asthma) History of controlled asthma for the prior 1 month if participant has asthma, defined by not exceeding 2 days of symptoms per week; not more than 2 days of albuterol/short acting betaagonist [SABA] use per week; and not wakening more than twice a month at night due to asthma symptoms Agrees to remain abstinent or use (or have their partner use) 2 acceptable methods of birth control from screening and through the duration of the study Unable to meet medication washout requirements History of chronic urticaria and/or chronic angioedema within prior 2 years History of anaphylaxis with cardiorespiratory symptoms with prior immunotherapy due to an unknown cause or to an inhalant allergen Unstable, uncontrolled or severe asthma, or has experienced a lifethreatening asthma attack or an occurrence of any clinical deterioration of asthma that resulted in emergency treatment, hospitalization due to asthma, or treatment with systemic corticosteroids (but allowing SABAs) at any time within prior 3 months History of chronic sinusitis during within prior 2 years Pregnant or breastfeeding, or expecting to conceive within the projected duration of the study Known history of allergy, hypersensitivity or intolerance to investigational medicinal products except for Dermatophagoides pteronyssinus (D. pteronyssinus) and/or Dermatophagoides farina (D. farina) or selfinjectable epinephrine Business or personal relationship with investigational site personnel or Sponsor who is directly involved with the conduct of the trial</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>